Material Agreement, Financial Obligation (Form 8-K)

Item 1.01 Entry into a Material Definitive Agreement.

On June 25, 2026, Disc Medicine, Inc. (the "Company") entered into a First Amendment to Loan Agreement (the "Amendment") to the Loan and Security Agreement dated as of November 6, 2024 (as amended, the "Loan Agreement") among the Company, the lender party thereto and Hercules Capital, Inc., as administrative agent and collateral agent ("Hercules") for the purpose of extending the periods during which future Advances (as defined in the Loan Agreement) may be drawn down. Pursuant to the Amendment, (a) the Company agreed to draw down $30,000,000 of the Tranche 1-B Advance (as defined in the Loan Agreement), (b) the existing $50,000,000 Tranche 1-C Advance (as defined in the Loan Agreement) was divided into a $25,000,000 loan available at the Company's option through March 31, 2027 and a $25,000,000 Tranche 1-D Advance that is available to the Company through April 30, 2027, and (c) the periods for drawing down the Tranche 2 Advance and Tranche 3 Advance were extended to December 15, 2027 and June 30, 2028, respectively, as set forth in the Amendment. Additionally, the Company and Hercules agreed to amend the minimum cash covenant terms to provide for an initial testing date of July 1, 2028, as well as certain other modifications set forth in the Amendment.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03.